早期帕金森病患者对左旋多巴的反应:LEAP研究的进一步观察
LEAP研究是一项双盲、安慰剂对照、随机、延迟起始试验,早期帕金森病患者随机接受左旋多巴/卡比多巴300/75 mg每日(早起始组)或安慰剂40周后同剂量左旋多巴/卡比多巴40周(延迟起始组)。事后分析显示,左旋多巴对运动迟缓、强直和震颤的改善幅度相近,22周时效应大于4周时;80周时早起始组出现运动反应波动的患者比例低于延迟起始组(23% vs 38%,p<0.01)。
要点
- 左旋多巴对早期帕金森病运动迟缓、强直和震颤的改善幅度相近。
- 22周时左旋多巴对上述3种症状的效应均大于4周时。
- 80周时早起始组运动反应波动患者比例低于延迟起始组(23% vs 38%)。
核心结论
- 在早期帕金森病患者中,左旋多巴对运动迟缓、强直和震颤的改善幅度相近;22周时效应大于4周时;80周时早起始组出现运动反应波动的患者少于延迟起始组。
研究设计与样本
- LEAP研究为双盲、安慰剂对照、随机、延迟起始试验,早期帕金森病患者随机接受左旋多巴/卡比多巴300/75 mg每日共80周(早起始组)或安慰剂40周后左旋多巴/卡比多巴300/75 mg每日共40周(延迟起始组)。
- 共222例随机至早起始组(基线平均±SD年龄64.8±8.7岁,71%男性),223例随机至延迟起始组(基线平均±SD年龄65.5±8.8岁,69%男性)。
主要发现
- 早起始组与延迟起始组从基线至第4周平均变化差异以Hedges g效应量表示:运动迟缓-0.33、强直-0.29、震颤-0.25,均提示有利于早起始组的小效应。
- 从基线至第22周,上述效应量分别为-0.49、-0.36、-0.44,为小至中等效应。
- 从基线至第40周,上述效应量分别为-0.32、-0.19、-0.27,为小效应。
- 第80周时,早起始组出现运动反应波动的患者为205例中46例(23%),延迟起始组为211例中81例(38%),p<0.01。
关键数值与推荐
- 本研究提供II级证据:左旋多巴对运动迟缓、强直和震颤的效应在治疗22周后大于4周时。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The Levodopa in EArly Parkinson's Disease (LEAP) study enabled us to conduct post hoc analyses concerning the effects of levodopa in patients with early Parkinson disease. METHODS: The LEAP study was a double-blind, placebo-controlled, randomized, delayed-start trial in which patients with early Parkinson disease were randomized to receive levodopa/carbidopa 300/75 mg daily for 80 weeks (early-start group) or to placebo for 40 weeks followed by levodopa/carbidopa 300/75 mg daily for 40 weeks (delayed-start group). We analyzed the effect of levodopa with the Unified Parkinson's Disease Rating Scale on bradykinesia, rigidity, and tremor. At week 80, participants answered 3 questions regarding motor response fluctuations. RESULTS: A total of 222 patients were randomized to the early-start group (mean ± SD age at baseline 64.8 ± 8.7 years; 71% male) and 223 to the delayed-start group (mean ± SD age at baseline 65.5 ± 8.8 years; 69% male). The difference between the early- and delayed-start groups in mean change from baseline to week 4, expressed as Hedges g effect size, was -0.33 for bradykinesia, -0.29 for rigidity, and -0.25 for tremor (for all symptoms indicating a small effect in favor of the early-start group); from baseline to week 22, respectively, -0.49, -0.36, and -0.44 (small to medium effect); and from baseline to week 40, respectively, -0.32, -0.19, and -0.27 (small effect). At 80 weeks, fewer patients in the early-start group (46 of 205 patients, 23%) experienced motor response fluctuations than patients in the delayed-start group (81 of 211, 38%; p < 0.01). DISCUSSION: In patients with early Parkinson disease, levodopa improves bradykinesia, rigidity, and tremor to the same order of magnitude. For all 3 symptoms, effects were larger at 22 weeks compared with 4 weeks. At 80 weeks, there were fewer patients with motor response fluctuations in the group that had started levodopa earlier. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the effect of levodopa on bradykinesia, rigidity, and tremor is larger after 22 weeks compared with 4 weeks of treatment. TRIAL REGISTRATION INFORMATION: ISRCTN30518857, EudraCT number 2011-000678-72.
引用
- Frequin HL, Schouten J, Verschuur CVM, et al. Levodopa Response in Patients With Early Parkinson Disease: Further Observations of the LEAP Study. Neurology. 2022. PMID: 36253105. doi:10.1212/WNL.0000000000201448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。